AI PRICE FORECAST
SYK Stock Forecast & AI Price Prediction
Stryker · Healthcare · Medical Devices
SYK live signal snapshot
Shares of SYK were last at $318.79, down 1.70% on the day, trading 18.1% below its 52-week high of $389.33 and 19.4% above its 52-week low of $267.00. Our AI model's current call on SYK is HOLD, with 69% confidence. The technical signals aren't aligned enough for a directional call yet. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $305.77, a -4.1% move from the last price.
SYK's 14-day RSI is 55.6 — healthy bullish momentum without being overextended. The MACD indicator sits over its signal line, and the histogram reading of 1.33 shows buying pressure building. With the 50-day average at $292.21, 9.4% under the 200-day's $322.38, the longer-term trend structure is still negative.
27 Wall Street analysts covering SYK put the average price target at $338.45 (range $275.00–$410.00), implying 6.2% upside from the current price. The current recommendation trend leans bullish: 22 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 8 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive SYK dashboard for numbers updated throughout today's session.
About Stryker
Stryker Corporation (SYK) is a medical devices company in the healthcare sector, headquartered in Portage, MI, United States. Stryker Corporation operates as a medical technology company in the United States and internationally. It has a market value of about $121.4 billion and roughly 56,000 full-time employees. Its beta of 0.77 means it has historically moved roughly in line with the market.
SYK performance vs. the market
SYK is down 9.3% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 10.2%, 21.7 points worse than the S&P 500. The direction has flipped lately — +12.8% over the past month versus −6.5% across three.
| Period | SYK | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +12.8% | +11.4% | −2.3% |
| 3 months | −6.5% | +12.2% | −2.3% |
| Year to date | −9.3% | +22.1% | +11.4% |
| 1 year | −10.2% | +28.3% | +11.5% |
Stryker financials at a glance
Stryker's most recent quarter (ended Sep 30, 2026) brought in $6.5 billion of revenue and net income of $753 million (a 11.5% net margin). Revenue was up 7.6% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 33.9 on trailing earnings of $9.39 per share. Trailing free cash flow was $3.7 billion, and total debt equals 66% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $6.5B | $753M |
| Jun 30, 2026 | $6.6B | $1.3B |
| Mar 31, 2026 | $6.0B | $745M |
| Dec 31, 2025 | $7.2B | $849M |
SYK vs. its peers
SYK's −9.3% this year ranks ahead of 2 of the 5 big healthcare names below. The strongest of the group this year is Edwards Lifesciences (EW, +24.1%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Stryker (SYK) | $318.79 | −9.3% | 33.9 | HOLD |
| Abbott Laboratories (ABT) | $109.29 | −12.8% | 40.8 | HOLD |
| Medtronic (MDT) | $101.61 | +5.8% | 25.0 | HOLD |
| Boston Scientific (BSX) | $45.13 | −52.7% | 19.0 | HOLD |
| Edwards Lifesciences (EW) | $105.81 | +24.1% | 61.5 | BUY |
| GE HealthCare Technologies (GEHC) | $82.60 | +0.7% | 17.5 | BUY |
SYK stock: common questions
What is the SYK stock price target?
27 Wall Street analysts put the average 12-month target at $338.45, in a range of $275.00–$410.00, versus a recent price of $318.79. Stock Pulse 247's model projects about $305.77 over the next month.
Is SYK a buy right now?
Our AI model currently rates SYK a HOLD at 69% confidence. Among analysts, 22 rate it Buy or Strong Buy, 8 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has SYK stock performed this year?
SYK is down 9.3% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 10.2%, 21.7 points worse than the S&P 500. The direction has flipped lately — +12.8% over the past month versus −6.5% across three.
What is SYK's 52-week high and low?
SYK has traded between $267.00 and $389.33 over the past 52 weeks; at $318.79 it is 18.1% below its 52-week high of $389.33 and 19.4% above its 52-week low of $267.00.
What sector is SYK in, and who are its peers?
SYK is in the healthcare sector (medical devices). Its largest peers on Stock Pulse 247 include Abbott Laboratories (ABT), Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW).
How accurate is the SYK forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines SYK's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.